In:
Oncology, S. Karger AG, Vol. 70, No. 5 ( 2006), p. 330-338
Abstract:
〈 i 〉 Background: 〈 /i 〉 We tested a sequential combination regimen using cisplatin and vinorelbine (PVn) followed by docetaxel as first-line chemotherapy in a phase II clinical trial in metastatic breast cancer (MBC). 〈 i 〉 Patients and Methods: 〈 /i 〉 Thirty-five patients were enrolled. Cisplatin 80 mg/m 〈 sup 〉 2 〈 /sup 〉 was given on day 1 and vinorelbine 30 mg/m 〈 sup 〉 2 〈 /sup 〉 on days 1 and 8 every 3 weeks for 4 cycles. Responding patients received docetaxel 75 mg/m 〈 sup 〉 2 〈 /sup 〉 every 21 days for a maximum of 4 cycles. Three patients were excluded from analysis because of death unrelated to treatment. 〈 i 〉 Results: 〈 /i 〉 After a median follow-up of 14 months, 32 patients completed the study. The overall response rate was 53.1%. Complete remission was seen in 5 patients (15.6%), partial response in 12 (37.5%), stable disease in 6 (18.75%), and progressive disease in 9 patients (28.1%). Median time to disease progression was 8 months (range 1–24). At 24 months, 12 (37.5%) patients were alive. A total of 183 cycles were administered. Febrile neutropenia was observed in 4 patients (2.2%). Grade II nephrotoxicity occurred in 12 cycles (6.5%) and grade III vomiting in 31/183 cycles (16.9%). 〈 i 〉 Discussion: 〈 /i 〉 PVn is a feasible non-anthracycline option as first-line chemotherapy in patients with metastatic breast cancer and has acceptable toxicity. The sequential addition of 4 cycles of docetaxel following 4 cycles of PVn did not improve the overall response rate and results.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2006
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink